DOJ closes probe into clinical trials for AstraZeneca’s Brilinta drug

The DOJ had been investigating whether the company manipulated the number of deaths from an opposing drug

When the U.S. Department of Justice (DOJ) opens a probe into a specific drug — especially one as potentially lucrative as AstraZeneca’s Brilinta —pharmaceutical companies are often left scrambling. But AstraZeneca is breathing a huge sigh of relief today, as the DOJ has cleared the company of any wrongdoing in conducting clinical trials.

The DOJ announced that it was closing a probe into Brilinta that it had opened in October 2013. The department had been trying to determine whether a major clinical trial called PLATO had been fairly conducted.

Assistant Editor

author image

Zach Warren

Zach Warren is Assistant Editor of InsideCounsel magazine, where he oversees online content submissions and administers InsideCounsel's enewsletters. Zach specializes in new media and multimedia...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.